Reduced-intensity chemotherapy with tyrosine kinase inhibitor followed by allogeneic transplantation is effective in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Citations

WEB OF SCIENCE

1
Citations

SCOPUS

1

초록

Background/Aims: To determine the effectiveness of tyrosine kinase inhibitor (TKI) plus reduced-intensity therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL), this retrospective study compared treatment outcomes and induction mortality according to backbone regimen intensity. Methods: The data of 132 patients diagnosed with Ph-positive ALL were retrospectively collected from five centers. Patients received imatinib plus intensive chemotherapy (modified VPD, KALLA1407, or hyper-CVAD) or reduced-intensity chemotherapy (EWALL) for curative purposes. This study analyzed 117 patients, of which 35,22,46, and 14 received modified VPD, KALLA1407, hyper-CVAD, and EWALL, respectively. All patients used imatinib as a TKI. Results: The median age of the patients who received reduced-intensity chemotherapy was 64.4 years, while that of the patients with intensive regimens was 47.5 years. There was no induction death in the reduced-intensity group, while nine patients died in the intensive therapy group. Major molecular response achievement tended to be higher in the intensive chemotherapy group than in the reduced-intensity group. More patients in the intensive chemotherapy group received allogeneic stem cell transplantation (allo-SCT). There was no statistically significant difference in long-term survival between the two groups in terms of relapse-free survival and overall survival rates. Conclusions: When imatinib plus reduced-intensity therapy was used as a frontline treatment, there was no inferiority in obtaining complete remission compared to imatinib plus intensive chemotherapy or significant difference in long-term survival. Since imatinib plus reduced-intensity therapy has limitations in obtaining a deep molecular response, proceeding to allo-SCT should be considered.

키워드

Philadelphia chromosome; Acute lymphoblastic leukemia; Tyrosine kinase inhibitor; Stem cell transplantation; HYPER-CVAD; 1ST-LINE THERAPY; SINGLE-CENTER; IMATINIB; COMBINATION; PONATINIB; SURVIVAL; ADULTS
제목
Reduced-intensity chemotherapy with tyrosine kinase inhibitor followed by allogeneic transplantation is effective in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
저자
Lee, Jung Min; Kim, Do Young; Cho, Hee Jeong; Moon, Joon Ho; Sohn, Sang Kyun; Shin, Ho Jin; Do, Young Rok; Heo, Mi Hwa; Kim, Min Kyoung; Park, Young Seob; Baek, Dong Won
DOI
10.3904/kjim.2024.227
발행일
2025-01
유형
Article
저널명
The Korean Journal of Internal Medicine
권
40
호
1
페이지
124 ~ 134